CN101821247A - 作为hsp90抑制剂的抗癌用5-(2-羟基苯基)四唑化合物 - Google Patents

作为hsp90抑制剂的抗癌用5-(2-羟基苯基)四唑化合物 Download PDF

Info

Publication number
CN101821247A
CN101821247A CN200880111766A CN200880111766A CN101821247A CN 101821247 A CN101821247 A CN 101821247A CN 200880111766 A CN200880111766 A CN 200880111766A CN 200880111766 A CN200880111766 A CN 200880111766A CN 101821247 A CN101821247 A CN 101821247A
Authority
CN
China
Prior art keywords
isopropyl
tetrazol
methoxy
diol
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880111766A
Other languages
English (en)
Chinese (zh)
Inventor
R·-Y·杨
S·M·阿利
M·A·阿什维尔
E·科勒赫
R·帕马
N·维斯特伦德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of CN101821247A publication Critical patent/CN101821247A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200880111766A 2007-10-12 2008-10-14 作为hsp90抑制剂的抗癌用5-(2-羟基苯基)四唑化合物 Pending CN101821247A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97960107P 2007-10-12 2007-10-12
US60/979601 2007-10-12
PCT/US2008/079755 WO2009049305A2 (en) 2007-10-12 2008-10-14 5- (2-hydroxyphenyl) tetrazoles as hsp90 inhibitors against cancer

Publications (1)

Publication Number Publication Date
CN101821247A true CN101821247A (zh) 2010-09-01

Family

ID=40473811

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880111766A Pending CN101821247A (zh) 2007-10-12 2008-10-14 作为hsp90抑制剂的抗癌用5-(2-羟基苯基)四唑化合物

Country Status (7)

Country Link
US (1) US7932279B2 (https=)
EP (1) EP2217580B1 (https=)
JP (1) JP4792128B2 (https=)
CN (1) CN101821247A (https=)
AT (1) ATE538105T1 (https=)
CA (1) CA2700893A1 (https=)
WO (1) WO2009049305A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115768422A (zh) * 2020-05-13 2023-03-07 诺沃亚桑托斯教授基金会 用于治疗癌症的泛素连接酶抑制剂

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2014034868A1 (ja) 2012-08-31 2014-03-06 株式会社エーピーアイ コーポレーション ビアリール化合物の製造方法
JP5881837B2 (ja) 2012-09-26 2016-03-09 株式会社エーピーアイ コーポレーション テトラゾール化合物の脱保護方法
KR20180011843A (ko) 2015-06-11 2018-02-02 바실리어 파마슈티카 인터내셔널 리미티드 유출-펌프 억제제 및 이의 치료적 용도
CN105418527A (zh) * 2015-12-28 2016-03-23 青岛友诚高新技术有限公司 一种具有抗乳腺导管癌活性的化合物及其制备方法、用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1486057A (en) * 1975-06-09 1977-09-14 Ici Ltd Hydroxyphenyl tetrazoles and their use in the extraction of metals
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6975843B2 (en) 2000-12-21 2005-12-13 Telefonaktiebolaget L M Ericsson (Publ) Method and an arrangement relating to telecommunications systems
US6962944B2 (en) 2001-07-31 2005-11-08 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US7074824B2 (en) 2001-07-31 2006-07-11 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
JPWO2003030937A1 (ja) * 2001-10-05 2005-01-20 小野薬品工業株式会社 ミトコンドリアルベンゾジアゼピン受容体アンタゴニストからなるストレス疾患の治療剤
GB0228417D0 (en) 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
EA009919B1 (ru) 2003-02-11 2008-04-28 Вернэлис (Кембридж) Лимитед Соединения изоксазола
MXPA05012377A (es) 2003-05-15 2006-05-25 Arqule Inc Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38.
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
GB0316546D0 (en) * 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
MXPA06004657A (es) * 2003-10-28 2006-06-27 Pharmacia Corp Combinaciones que comprenden un inhibidor de hsp90 y un inhibidor de fosfodiesterasa para tratar o prevenir la neoplasia.
JPWO2005063222A1 (ja) * 2003-12-26 2007-07-19 協和醗酵工業株式会社 Ｈｓｐ９０ファミリー蛋白質阻害剤
FR2865736B1 (fr) 2004-02-02 2006-07-14 Synt Em Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese
JP2005225787A (ja) 2004-02-12 2005-08-25 Nippon Kayaku Co Ltd Ｈｓｐ９０阻害剤
WO2006011052A1 (en) 2004-07-23 2006-02-02 Pharmacia & Upjohn Company Llc Method for the racemization of 2-trifluoro-2h-chromene-3-carboxylic acids
AR050084A1 (es) 2004-07-27 2006-09-27 Novartis Ag Derivados de bencimidazolona como inhibidores de hsp90
DE102004039280A1 (de) 2004-08-13 2006-02-23 Merck Patent Gmbh 1,5-Diphenyl-pyrazole
JP2008517064A (ja) 2004-10-19 2008-05-22 アークル インコーポレイテッド Ｐ３８ｍａｐキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成
WO2006055760A1 (en) * 2004-11-18 2006-05-26 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DE102005007304A1 (de) 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate
JP2006306755A (ja) 2005-04-27 2006-11-09 Nippon Kayaku Co Ltd 新規なピラゾール誘導体とそれを有効成分とするｈｓｐ９０阻害剤
JP2008540395A (ja) 2005-05-03 2008-11-20 ファイザー・インク アミドレソルシノール化合物
JP5178515B2 (ja) * 2005-08-12 2013-04-10 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するピラゾール化合物
WO2007094819A2 (en) 2005-08-18 2007-08-23 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP1951679B1 (en) * 2005-08-18 2015-02-18 Synta Pharmaceuticals Corp. Imidazole compounds that modulate hsp90 activity
EP2013218A2 (en) 2006-04-17 2009-01-14 Arqule, Inc. Raf inhibitors and their uses

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115768422A (zh) * 2020-05-13 2023-03-07 诺沃亚桑托斯教授基金会 用于治疗癌症的泛素连接酶抑制剂

Also Published As

Publication number Publication date
US7932279B2 (en) 2011-04-26
US20090130117A1 (en) 2009-05-21
JP2011500603A (ja) 2011-01-06
WO2009049305A2 (en) 2009-04-16
JP4792128B2 (ja) 2011-10-12
EP2217580B1 (en) 2011-12-21
CA2700893A1 (en) 2009-04-16
EP2217580A2 (en) 2010-08-18
WO2009049305A3 (en) 2009-07-02
ATE538105T1 (de) 2012-01-15

Similar Documents

Publication Publication Date Title
CN113329999B (zh) 具有雄激素受体降解活性的新型取代的喹啉-8-甲腈衍生物及其用途
JP7653166B2 (ja) ＣＣＲ８阻害剤を使用してＴｒｅｇｓを標的とする方法および組成物
JP5362565B2 (ja) オピオイド受容体のアンタゴニストまたはインバースアゴニストである新規化合物
US11084784B2 (en) ROR-gamma modulators and uses thereof
CN102099355B (zh) 苯基和苯并二氧杂环己烯基取代的吲唑衍生物
DE69719191T2 (de) Tetrahydroisoquinoline derivate als modulatoren von dopamine d3 rezeptoren
JP2008526887A (ja) カンナビノイド受容体に作用する新規なヘテロピロール類似体
JP2013507416A (ja) Ｍｄｍ２−ｐ５３相互作用の阻害剤として新規なｎ−置換ピロリジン
JP2010514689A (ja) 癌、炎症およびウイルス感染症の処置のためのｃｄｋ阻害剤としてのヘテロアリール−ヘテロアリール化合物
JP2010506918A (ja) ヒスタミンｈ３受容体に関連する障害の処置に有用なヒスタミンｈ３受容体のビフェニルスルホニルおよびフェニル−ヘテロアリールスルホニルモジュレーター
CN101821247A (zh) 作为hsp90抑制剂的抗癌用5-(2-羟基苯基)四唑化合物
KR102939061B1 (ko) 화합물 및 mif 억제제로서의 용도
SG11202110545TA (en) Inhibitors of notch signalling pathway and use thereof in treatment of cancers
JP2011500603A5 (https=)
JP2022519771A (ja) ファルネソイドｘ受容体モジュレータとして有用な置換アミド化合物
KR101827660B1 (ko) 플루오로페닐 피라졸 화합물
CZ36194A3 (en) Amidetetrazoles inhibiting cholesterol acyltransferase
CN102753538B (zh) 磺内酰胺衍生物
JP3786983B2 (ja) ピロリジノン誘導体
CN103328446B (zh) 用于治疗癌症的新的4-氨基-n-羟基-苯甲酰胺
WO2019036024A1 (en) 2- (1,1'-BIPHENYL) -1H-BENZO [D] IMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS AGONISTS OF APELIN AND APJ FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
CN102307852B (zh) 环状胺化合物
HK40035913B (zh) 用於治疗癌症、视网膜病症和心肌病的三取代嘧啶化合物和组合物
CN101528684A (zh) 适用于治疗组胺h3受体相关病症的组胺h3受体的联苯磺酰基和苯基-杂芳基磺酰基调节剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100901